DE60044087D1 - Verfahren und mittels zur manipulierung der expression des uncoupling proteins - Google Patents

Verfahren und mittels zur manipulierung der expression des uncoupling proteins

Info

Publication number
DE60044087D1
DE60044087D1 DE60044087T DE60044087T DE60044087D1 DE 60044087 D1 DE60044087 D1 DE 60044087D1 DE 60044087 T DE60044087 T DE 60044087T DE 60044087 T DE60044087 T DE 60044087T DE 60044087 D1 DE60044087 D1 DE 60044087D1
Authority
DE
Germany
Prior art keywords
expression
manipulating
expressed
ucp
uncoupling protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60044087T
Other languages
English (en)
Inventor
Martha K Newell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Vermont
University of Vermont and State Agricultural College
Original Assignee
University of Vermont
University of Vermont and State Agricultural College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Vermont, University of Vermont and State Agricultural College filed Critical University of Vermont
Application granted granted Critical
Publication of DE60044087D1 publication Critical patent/DE60044087D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
DE60044087T 1999-06-23 2000-06-22 Verfahren und mittels zur manipulierung der expression des uncoupling proteins Expired - Lifetime DE60044087D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14057499P 1999-06-23 1999-06-23
PCT/US2000/017245 WO2000078941A2 (en) 1999-06-23 2000-06-22 Methods and products for manipulating uncoupling protein expression

Publications (1)

Publication Number Publication Date
DE60044087D1 true DE60044087D1 (de) 2010-05-12

Family

ID=22491870

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60044087T Expired - Lifetime DE60044087D1 (de) 1999-06-23 2000-06-22 Verfahren und mittels zur manipulierung der expression des uncoupling proteins

Country Status (9)

Country Link
US (2) US7816319B2 (de)
EP (1) EP1194168B1 (de)
JP (1) JP2003503319A (de)
AT (1) ATE462447T1 (de)
AU (1) AU780815B2 (de)
CA (1) CA2375508A1 (de)
DE (1) DE60044087D1 (de)
HK (1) HK1047032A1 (de)
WO (1) WO2000078941A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
AU780815B2 (en) 1999-06-23 2005-04-21 University Of Vermont And State Agricultural College, The Methods and products for manipulating uncoupling protein expression
GB9930100D0 (en) * 1999-12-17 2000-02-09 Smithkline Beecham Plc New use
WO2004111199A2 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
CA2602562C (en) 2005-03-25 2015-07-07 Alt Solutions, Inc. Modulation of telomere length in telomerase positive cells and cancer therapy
GEP20115226B (en) 2005-04-26 2011-06-10 Pfizer P-cadherin antibodies
JP2008539238A (ja) * 2005-04-28 2008-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 治療用二機能性化合物
WO2006118821A2 (en) * 2005-05-02 2006-11-09 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition
US8609623B2 (en) 2005-05-18 2013-12-17 Alt Solutions Inc. Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
US20070032383A1 (en) * 2005-07-27 2007-02-08 Newell M K Systems, methods, and compositions for modifying the metabolism of plants and of euucaryotic microbes
GB0610317D0 (en) * 2006-05-24 2006-07-05 Medical Res Council Antiparasitic compounds and compositions
WO2009021034A2 (en) * 2007-08-06 2009-02-12 University Of Rochester Methods of treating b-cell cancers
CA2716321A1 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
AU2009271579A1 (en) 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
WO2010051347A1 (en) * 2008-10-31 2010-05-06 David Sheikh-Hamad A method for cardioprotection
US8450090B2 (en) 2009-10-06 2013-05-28 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for promoting fatty acid production in plants
WO2011075665A2 (en) * 2009-12-18 2011-06-23 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9938279B2 (en) * 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935450A (en) * 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
US4724234A (en) * 1982-09-17 1988-02-09 Therapeutical Systems Corp. Method for producing oncolysis
US5585363A (en) * 1987-05-05 1996-12-17 City Of Hope Circumvention of human tumor drug resistance
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
EP0702554A1 (de) * 1993-06-07 1996-03-27 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Verwendung eines mhc-klasse i-suppressor-wirkstoffes zur behandlung von autoimmun-erkrankungen und transplantat-abstossung
CA2260766A1 (en) 1996-07-12 1998-01-22 Emory University Regulation of apoptosis and in vitro model for studies thereof
WO1998031396A1 (en) * 1997-01-15 1998-07-23 Duke University Respiration uncoupling protein
WO1998045313A1 (en) * 1997-04-04 1998-10-15 Amylin Pharmaceuticals, Inc. Novel uncoupling protein and methods of use
WO1998045438A1 (en) * 1997-04-09 1998-10-15 Beth Israel Deaconess Medical Center Ucp3: an uncoupling protein homologue
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
EP1077724A2 (de) 1998-04-17 2001-02-28 The University Of Vermont Verfahren und produkte die mit metabolischen interaktionen in krankheiten zusammenhangen
WO2000047617A1 (en) 1999-02-09 2000-08-17 Lexicon Genetics Incorporated Human uncoupling proteins and polynucleotides encoding the same
AU780815B2 (en) 1999-06-23 2005-04-21 University Of Vermont And State Agricultural College, The Methods and products for manipulating uncoupling protein expression
US7105718B2 (en) * 2000-03-31 2006-09-12 The Regents Of The University Of Colorado Compositions and methods for regulating metabolism in plants
JP2006512041A (ja) 2001-10-12 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド， ア ボディー コーポレイト 活性酸素を用いる共刺激分子発現の調節のための方法
US7341559B2 (en) * 2002-09-14 2008-03-11 Masimo Corporation Pulse oximetry ear sensor

Also Published As

Publication number Publication date
US7816319B2 (en) 2010-10-19
US20110206755A1 (en) 2011-08-25
AU5760000A (en) 2001-01-09
EP1194168A2 (de) 2002-04-10
WO2000078941A2 (en) 2000-12-28
CA2375508A1 (en) 2000-12-28
JP2003503319A (ja) 2003-01-28
AU780815B2 (en) 2005-04-21
HK1047032A1 (zh) 2003-02-07
US20060247199A1 (en) 2006-11-02
EP1194168B1 (de) 2010-03-31
ATE462447T1 (de) 2010-04-15
WO2000078941A3 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
ATE462447T1 (de) Verfahren und mittels zur manipulierung der expression des uncoupling proteins
WO2006127809A3 (en) Methods for expansion and analysis of cultured hematopoietic stem cells
PT1685243E (pt) Linhas celulares aviárias imortalizadas para a produção de vírus
WO2003104418A3 (en) RECONSTITUTED POLYPEPTIDES
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE469219T1 (de) Zusammensetzungen, methoden und reagentien zur nukleinsäureisolierung mittels oberflächenaktiven substanzen und proteasen
DE69739996D1 (de) Methoden und Zusammensetzungen zur Herstellung von Polypeptiden
AU6380001A (en) Porous ferro- or ferrimagnetic glass particles for isolating molecules
DK15182A (da) Fremgangsmaade til fremstilling af recombinant-dna
DE602005022056D1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
ATE430807T1 (de) Verfahren zur kultivierung von circovirus
WO2002002783A3 (en) Expression vectors
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
MXPA02007665A (es) Trazado de despliegue diferencial de proteinas.
DE60111783D1 (de) Verfahren zur herstellung und reinigung von sekretierten proteinen und herstellung von protein-arrays
ATE268810T1 (de) Methode zur zellyse
DK1272669T3 (da) High-throughput screening af udtrykte DNA-biblioteker i trådsvampe
DK1082423T3 (da) Cyclin E2-gener og -proteiner
ATE313068T1 (de) Thromboplastin-reagenzien und verfahren zur herstellung und anwendung derselben
ATE513851T1 (de) Menschliches gen zur fruchtbarkeit entscheidend
WO2004081033A3 (en) Synthesis of proteins by cell-free protein expression
ATE299944T1 (de) System zur herstellung von proteinen
WO2005089509A3 (en) High throughput assay systems and methods for identifying agents that alter expression of cellular proteins
DE60326494D1 (de) Mannosyl(1-2)glycosyl(1-2)glycerat zur stabilisierung und konservierung von biomaterialien
DE60113660D1 (de) G-protein gekoppelter rezeptor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition